United States Blood Cancer Drugs Market to Reach USD 113.5 Billion by 2031 | Strong 7.8% CAGR | North America Leads with 45% Share | Key Players: Amgen, AstraZeneca, Takeda, Bristol-Myers Squibb, Gilead Sciences

Blood Cancer Drugs Market Overview

The Global Blood Cancer Drugs Market reached USD 63 billion in 2022 and is projected to grow significantly to USD 113.5 billion by 2031, exhibiting a CAGR of 7.8% during 2024-2031. The market growth is primarily driven by the rising prevalence of blood cancers, continuous advancements in cancer research, and the development of targeted therapies, immunotherapies, and personalized medicine. Increasing awareness among patients and healthcare providers, along with enhanced diagnostic capabilities, is further supporting market expansion.

Blood cancer drugs include therapies for leukemia, lymphoma, and multiple myeloma, encompassing conventional chemotherapies as well as next-generation targeted therapies and immune-modulating drugs. Innovations in T-cell therapies, bispecific antibodies, and gene therapies are redefining treatment paradigms, offering improved efficacy and reduced side effects. For instance, Siren Biotechnology, in May 2023, introduced its Universal AAV Immuno-Gene Therapy, combining AAV gene therapy with cytokine immunotherapy to enhance anti-tumor immunity. Similarly, in March 2023, AbbVie received FDA approval for EPKINLYTM, the first T-cell engaging bispecific antibody for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), highlighting the growing focus on advanced targeted therapies.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/blood-cancer-drugs-market?Juli

Recent Developments:

✅ October 2025: Novartis announced the launch of its next-generation CAR-T therapy for multiple myeloma, demonstrating enhanced efficacy and reduced cytokine release syndrome in clinical trials.

✅ September 2025: Bristol-Myers Squibb received FDA approval for its bispecific antibody targeting B-cell malignancies, providing a new immunotherapy option for relapsed or refractory lymphoma patients.

✅ August 2025: Gilead Sciences expanded its portfolio with the acquisition of a gene-editing startup focused on blood cancer therapies, strengthening its R&D capabilities in CAR-T and AAV-based immunotherapies.

✅ June 2025: Pfizer introduced an oral targeted therapy for chronic lymphocytic leukemia (CLL) with improved safety profiles and enhanced patient compliance, supporting outpatient treatment options.

✅ March 2025: Roche launched a combination therapy for acute myeloid leukemia (AML), integrating its targeted kinase inhibitor with immune checkpoint modulators, improving response rates in clinical studies.

Mergers & Acquisitions:

✅ November 2025: AbbVie completed the acquisition of a biotech company specializing in bispecific antibodies for hematologic cancers, expanding its immuno-oncology pipeline.

✅ September 2025: Johnson & Johnson partnered with a European gene therapy firm to co-develop next-generation AAV-based treatments for rare blood cancers.

✅ June 2025: Amgen acquired a clinical-stage hematology-focused startup to accelerate development of CAR-T and other cellular therapies targeting leukemia and lymphoma.

Speak to Our Analyst and Get Customization in the report as per your requirements:- https://www.datamintelligence.com/customize/blood-cancer-drugs-market?Juli

Key Players:

• Amgen Inc. - Holds 14.2% market share, driven by its extensive portfolio of hematology therapies, CAR-T development programs, and strategic acquisitions in cellular immunotherapies.

• AstraZeneca Plc - Holds 12.8% market share, supported by its targeted therapy pipelines for leukemia and lymphoma and robust global oncology R&D initiatives.

• Takeda Pharmaceutical Company Ltd - Holds 11.5% market share, fueled by its immuno-oncology and small-molecule targeted therapies, along with acquisitions expanding its hematology footprint.

• Bayer AG - Holds 10.3% market share, backed by its gene therapy and precision medicine focus for hematologic malignancies, and strong collaborations with biotech firms.

• Celgene Corporation - Holds 9.7% market share, recognized for its leading multiple myeloma and lymphoma therapies and continuous innovation in combination regimens.

• Eli Lilly - Holds 8.9% market share, driven by its development of bispecific antibodies, kinase inhibitors, and clinical-stage hematology candidates.

• Bristol-Myers Squibb Company - Holds 11.0% market share, supported by its broad immuno-oncology portfolio, including CAR-T and checkpoint inhibitors for blood cancers.

• Gilead Sciences Inc. - Holds 9.2% market share, fueled by its acquisitions in cell therapy and expansion of its CAR-T and AAV-based treatment platforms.

• Daiichi Sankyo Company Ltd - Holds 6.7% market share, recognized for its targeted antibody-drug conjugates and clinical development programs in hematologic malignancies.

• UCB SA - Holds 5.7% market share, supported by its emerging pipeline in blood cancer therapies and partnerships to accelerate clinical-stage development.

Market Segmentation:

➥By Type:
Leukemia dominates with a 35% share, driven by high prevalence and increasing demand for targeted therapies and CAR-T treatments. Non-Hodgkin lymphoma accounts for 30%, fueled by rising incidence rates and adoption of immunotherapies. Hodgkin lymphoma holds 15%, supported by novel antibody-drug conjugates and combination therapies. Myeloma represents 20%, driven by multiple myeloma treatment innovations, including proteasome inhibitors and immunomodulatory drugs.

➥By Drugs Type:
Rituxan/Mabthera (Rituximab) leads with 18%, owing to widespread use in B-cell malignancies. Gleevec/Glivec (Imatinib) holds 12%, supported by chronic myeloid leukemia therapy adoption. Revlimid (Lenalidomide) captures 15%, Velcade (Bortezomib) 10%, and Tasigna (Nilotinib) 8%, driven by targeted therapy and hematology pipeline growth. Pomalyst (Pomalidomide) and Vidaza (Azacitidine) account for 5% and 4%, respectively. Kyprolis (Carfilzomib) holds 6%, Adcetris (Brentuximab Vedotin) 5%, and other drugs collectively contribute 17% to the market.

➥By Route of Administration:
Oral administration dominates with 55%, reflecting the preference for convenient, outpatient-friendly therapies. Parenteral routes account for 40%, used in hospital and infusion center settings for monoclonal antibodies and cytotoxic drugs. Other routes, including subcutaneous or intrathecal delivery, hold 5% of the market.

➥By End User:
Hospitals lead with 65% share, being primary centers for administration of complex therapies like CAR-T, monoclonal antibodies, and infusion treatments. Clinics account for 20%, supporting outpatient care and follow-up therapy. Ambulatory surgical centers capture 15%, focusing on minimally invasive procedures and specialized hematology services.

Buy Now & Unlock 360° Market Intelligence:- https://www.datamintelligence.com/buy-now-page?report=blood-cancer-drugs-market?Juli

Regional Insights:

North America - Holds the largest share at 45% of the global blood cancer drugs market, driven by high prevalence of hematologic malignancies, advanced healthcare infrastructure, strong presence of key pharmaceutical players, and rapid adoption of innovative therapies such as CAR-T, bispecific antibodies, and targeted small molecules. The U.S. dominates the region, supported by favorable reimbursement policies and robust R&D investment in oncology.

Europe - Accounts for 25%, fueled by growing awareness of blood cancers, government initiatives for cancer care, and rising adoption of precision medicine. Key contributors include Germany, France, the UK, and Italy, where advanced healthcare facilities and strong clinical trial networks support therapy uptake.

Asia-Pacific - Represents 20%, with high growth potential at a CAGR above the global average due to increasing cancer incidence, expanding healthcare infrastructure, rising affordability of therapies, and growing awareness about novel treatment options in countries such as China, Japan, and India. Urbanization and rising healthcare expenditure are accelerating market expansion.

Latin America - Holds 6%, driven by gradual improvements in healthcare access, rising diagnosis rates, and increasing availability of advanced therapies in countries like Brazil and Mexico.

Middle East & Africa - Accounts for 4%, with market growth supported by rising healthcare investments, improved oncology infrastructure, and increasing adoption of innovative cancer drugs, particularly in GCC countries and South Africa.

Market Dynamics:

Drivers:
The global blood cancer drugs market is primarily driven by the rising prevalence of hematologic malignancies such as leukemia, lymphoma, and myeloma. Advances in targeted therapies, immunotherapies, and CAR-T cell treatments are increasing the efficacy and safety of blood cancer treatments, further fueling market growth. The demand for personalized medicine and precision oncology approaches is also encouraging adoption, while increasing awareness of early diagnosis and improved healthcare access supports therapy uptake.

Restraints:
High treatment costs, including expensive biologics and advanced therapies, pose significant barriers in price-sensitive regions. Limited reimbursement coverage in emerging markets and regulatory complexities can delay drug approvals, hindering market penetration. Additionally, adverse effects associated with certain therapies, such as cytotoxicity and immune-related complications, may limit patient compliance.

Opportunities:
The market presents significant opportunities for the development of next-generation therapies, including bispecific antibodies, antibody-drug conjugates, and gene-modified cell therapies. Expanding healthcare infrastructure in emerging economies, rising investments in oncology R&D, and partnerships between pharmaceutical companies and biotech firms are expected to drive market growth. There is also potential for combination therapies and novel drug delivery systems to enhance patient outcomes and expand market reach.

Trends:
The market is witnessing a strong trend toward oral targeted therapies and outpatient-friendly regimens that improve patient convenience and adherence. Increasing collaborations between pharmaceutical companies and research institutions are accelerating innovation. Digital health integration, such as telemedicine and AI-driven diagnostics, is being used to monitor treatment responses and optimize personalized therapy plans. Additionally, patient-centric care models and growing awareness of clinical trial participation are shaping the competitive landscape.

Key Developments:

January 2025: Acalabrutinib (Calquence®) in combination with bendamustine and Rituximab received full traditional approval as first‐line therapy for adults with previously untreated Mantle Cell Lymphoma (MCL), marking an important expansion beyond its prior conditional approval.

February 2025: Brentuximab Vedotin (Adcetris®) in combination with Lenalidomide and Rituximab was approved for adults with relapsed or refractory Large B‐Cell Lymphoma (LBCL) including diffuse LBCL, indolent‐derived LBCL, and high‐grade B‐cell lymphoma who are ineligible for stem cell transplant or CAR‐T therapy.

August 2025: Lisocabtagene Maraleucel (Breyanzi®), a CAR‐T cell therapy, had its supplemental biologics license application (sBLA) accepted for use in relapsed or refractory Marginal Zone Lymphoma (MZL), potentially making it the first CAR‐T therapy approved for this lymphoma subtype.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.